Supporting information

Lyophilized amorphous dispersion of telmisartan in a combined carrier-alkalizer system: formulation development and *in vivo* study

Khater A. S. Al-Japairai [a,c], Hala M. Alkhalidi [b], Syed Mahmood [a], Samah H. Almurisi [c], Abd Almonem Doolaanea [c], Taha A. Al-Sindi [d], Bappaditya Chatterjee [*c,e]

[a] Department of Pharmaceutical Engineering, Faculty of Chemical and Process Engineering Technology, University Malaysia Pahang, Gambang 26300, Malaysia

[b] Department of Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Saudi Arabia

[c] Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan 25200, Malaysia

[d] Department of Basic Medical Science, Kulliyyah of Medicine, International Islamic University Malaysia (IIUM), Kuantan 25200, Malaysia

[e] SPP School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India



Figure S1. Statistical analysis of in vitro dissolution of solid dispersion (SD) formulation of telmisartan at 15 min by one way ANOVA. Error indicated standard deviation of mean. Bars sharing the same letter are not significantly different according to Tukey test.



Figure S2. FTIR spectra of three solid dispersed telmisartan A (F1), B (F2) and C (F3) at three time points of accelerated stability study (0 day, 1 month and 2 months).